This study is looking into how well Cannabidiol Oral Solution (CBD-OS) works as an add-on treatment for adults with Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy. Researchers want to see if gradually increasing the dose of CBD-OS can help reduce seizures. You might be able to join if you are an adult (18 years or older) with a confirmed LGS diagnosis, have had seizures recently, and haven't used CBD-OS in the last three months. The study will consider it a success if a significant number of participants see their major motor seizures reduced by 50% or more over 28 days by the end of the 24-week treatment period. The current status of this study is unclear, but it plans to enroll about 40 participants.

Study design

This is a Phase 3b/Phase 4 interventional study, meaning it's testing a treatment that has already shown some promise. It plans to enroll about 40 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at the end of the 24-week treatment period, but further follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.